Shilpa Medicare receives Eurasia GMP approval for 2 Telangana units

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-12-28 06:00 GMT   |   Update On 2024-12-28 06:00 GMT

Karnataka: In a BSE filing, Shilpa Medicare informed that its Unit IV and Unit VII in Telangana have received Good Manufacturing Practice (GMP) approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan, and Armenia.

The GMP inspection was conducted by the Ministry of Health, Belarus, in October in both units, as part of the GMP certification process for the Eurasian Economic Union.

This approval will open up significant business opportunities for the company in these countries.

"This is to inform you that Shilpa Medicare Limited, Unit IV, Jadcherla, Telangana, India and Shilpa Medicare Ltd, Unit VII, Nacharam, Hyderabad, Telangana, India had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024," the Company stated.  

Read also: Shilpa Medicare gets CDSCO panel nod to conduct Phase III clinical trials for Recombinant Human Albumin 20%  

Unit IV of Shilpa Medicare Lid. is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets.   
Unit VII of Shilpa Medicare Ltd. is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.
Medical Dialogues team had earlier reported that the Company had received the GMP Certification after the successful closure of the EMA, Europe inspection at Unit 7, Nacharam, Hyderabad, Telangana, India.   

Read also: Shilpa Medicare receives Europe GMP Certification for Hyderabad facility   

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments.

Read also: Shilpa Medicare-Zydus JV gets USFDA nod for Imkeldi for certain forms of leukemia, other cancers

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News